The OPPA, a district branch of the American Psychiatric Association, is a statewide medical specialty organization whose more than 1,000 physician members specialize in the diagnosis, treatment and prevention of mental illnesses, including substance use disorders.
With only two weeks to implement, the State of Ohio Pharmacy board notified prescribers, just yesterday, that beginning Dec. 29, 2017, the diagnosis/procedure code requirements are effective for all opioid prescriptions. The requirements for all other controlled substances go into effect on June 1, 2018.
Sunovion Pharmaceuticals last month announced that the FDA has accepted for review a New Drug Application (NDA) for dasotraline-a novel dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) for the treatment of ADHD in children and adults .
It’s Giving Tuesday! Celebrated on the Tuesday following Thanksgiving (in the U.S.) and the widely recognized shopping events Black Friday and Cyber Monday, #GivingTuesday kicks off the charitable season, when many focus on their holiday and end-of-year giving. Please remember the Ohio Psychiatric Physicians Foundation (OPPF) on this upcoming #GivingTuesday, by making a contribution on Tues., Nov. 27. Read More
Research Watch is an initiative by the residents of Case Western Reserve University/University Hospitals Cleveland Medical Center in the form of a monthly e-publication, which aims to inform psychiatry residents and faculty of notable articles published in prominent research and educational journals, with the hope of promoting a culture of incorporating latest research in our psychiatric worldview. Read More
For those with expertise in the use of clozapine this is an opportunity to collaborate with others who also have expertise and would like to see its appropriate use increase for the 20-30% of persons with treatment resistant schizophrenia. Read More
December 18, 2017
January 8, 2018